TBC AstraZeneca Pty Ltd
Product name
TBC
Sponsor
Accepted date
Apr-2024
Active ingredients
trastuzumab deruxtecan
Proposed indication
ENHERTU is indicated for the treatment of unresectable or metastatic HER2-positive solid tumours
Application type
C (new indication)
Publication date
Apr-2024
Provisional registration
Involves early access to vital and life-saving medicines through time-limited registration.